More Company News

Allergy Therapeutics

Positive top line results from G309 exploratory field trial
25 Oct 2021Read More

Allergy Therapeutics

Preliminary FY21 results
23 Sep 2021Read More

Allergy Therapeutics

Secondary endpoints from VLP Peanut 001
13 Sep 2021Read More

Allergy Therapeutics

Successful primary outcome of VLP Peanut 001
03 Aug 2021Read More

Allergy Therapeutics

Trading update for the year ended 30 June 2021
14 Jul 2021Read More

Allergy Therapeutics

Pre-close trading update
24 Jun 2021Read More

Allergy Therapeutics

Completion of treatment phase in G309 study
06 May 2021Read More

Allergy Therapeutics

Interim H121 results
03 Mar 2021Read More

Allergy Therapeutics

H121 trading update and notice of results
13 Jan 2021Read More

Allergy Therapeutics

Initiation of peanut allergy biomarker study
05 Jan 2021Read More

1 2
Return to Allergy Therapeutics
© 2019-21 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).